Semaglutide + Placebo (semaglutide)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Metabolism and Nutrition Disorder

Conditions

Metabolism and Nutrition Disorder, Overweight or Obesity

Trial Timeline

Jun 4, 2018 → Mar 5, 2021

NCT ID

NCT03548935

About Semaglutide + Placebo (semaglutide)

Semaglutide + Placebo (semaglutide) is a phase 3 stage product being developed by Novo Nordisk for Metabolism and Nutrition Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03548935. Target conditions include Metabolism and Nutrition Disorder, Overweight or Obesity.

What happened to similar drugs?

5 of 19 similar drugs in Metabolism and Nutrition Disorder were approved

Approved (5) Terminated (2) Active (14)

✅Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved

✅cyclosporine micro-emulsionNovartisApproved

✅Fluvastatin sodiumNovartisApproved

🔄liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3

🔄liraglutide + placeboNovo NordiskPhase 3

🔄Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3

🔄Semaglutide + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04916470	Phase 3	Completed	Jun 15, 2021	Oct 11, 2023	Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
NCT04777409	Phase 3	Active	May 18, 2021	Jan 23, 2026	Early Alzheimer´s Disease
NCT04865770	Phase 3	Completed	Apr 28, 2021	Nov 21, 2024	Diabetes Mellitus, Type 2
NCT04788511	Phase 3	Completed	Mar 16, 2021	Apr 18, 2023	Obesity
NCT04251156	Phase 3	Completed	Dec 8, 2020	Aug 23, 2022	Overweight
NCT04560998	Phase 3	Completed	Oct 1, 2020	Jul 12, 2024	Diabetes Mellitus, Type 2
NCT04032197	Phase 1	Completed	Aug 12, 2019	Jun 6, 2023	Diabetes Mellitus, Type 2
NCT03989232	Phase 3	Completed	Jun 19, 2019	Nov 9, 2020	Diabetes Mellitus, Type 2
NCT03987451	Phase 2	Completed	Jun 18, 2019	Jun 10, 2021	Non-alcoholic Steatohepatitis
NCT03819153	Phase 3	Completed	Jun 17, 2019	Jan 9, 2024	Diabetes Mellitus, Type 2
NCT03914326	Phase 3	Completed	Jun 17, 2019	Aug 23, 2024	Diabetes Mellitus, Type 2
NCT03811561	Phase 3	Active	May 8, 2019	Nov 7, 2027	Diabetes Mellitus, Type 2
NCT03811574	Phase 3	Completed	Jan 21, 2019	Nov 20, 2020	Overweight
NCT03574597	Phase 3	Completed	Oct 24, 2018	Jun 29, 2023	Overweight
NCT03693430	Phase 3	Completed	Oct 5, 2018	Mar 23, 2021	Overweight
NCT03611582	Phase 3	Completed	Aug 1, 2018	Apr 28, 2020	Overweight
NCT03548935	Phase 3	Completed	Jun 4, 2018	Mar 5, 2021	Metabolism and Nutrition Disorder

Competing Products

20 competing products in Metabolism and Nutrition Disorder

See all competitors

Product	Company	Stage	Hype Score
mRNA-3704	Moderna	Phase 2	0
E2609	Eisai	Phase 1	29
E2006	Eisai	Phase 1	29
AZD3480 + Placebo + Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)	AstraZeneca	Phase 1	29
Xuezhikang Capsule + Atorvastatin Calcium Tablets	AstraZeneca	Approved	43
Rabeprazole or Esomeprazole or Lanzoprazole	AstraZeneca	Pre-clinical	26
cyclosporine micro-emulsion	Novartis	Approved	35
Fluvastatin sodium	Novartis	Approved	43
NNC0165-1562 + placebo	Novo Nordisk	Phase 1	29
liraglutide	Novo Nordisk	Phase 1	29
NNC9204-0530 + placebo	Novo Nordisk	Phase 1	29
liraglutide + placebo	Novo Nordisk	Phase 1	29
liraglutide + placebo + liraglutide + placebo	Novo Nordisk	Phase 3	40
liraglutide + placebo	Novo Nordisk	Phase 3	40
Liraglutide 3.0 mg + Placebo	Novo Nordisk	Phase 3	40
liraglutide + orlistat + placebo	Novo Nordisk	Phase 2	35
NNC 0070-0002-0453 + '2-0453 + placebo	Novo Nordisk	Phase 1	21
NNC0194-0499 + Placebo	Novo Nordisk	Phase 1	29
Semaglutide + Placebo	Novo Nordisk	Phase 3	40
liraglutide + placebo	Novo Nordisk	Phase 3	40